Business Acquisition [Axis] Business Acquisition [Axis] Liability from in-licensing agreements Liabilities From-In-Licensing Agreements Liabilities From-In-Licensing Agreements Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Deferred tax asset (note 14) Deferred Income Tax Assets, Net Deferred Financing Fees Deferred Financing Costs [Policy Text Block] Deferred Financing Costs Policy Text Block. IPR&D Indefinite Lived Intangible Assets In Process Research and Development [Member] Information by major type or class of indefinite-lived intangible assets. In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Other Other Accounts Payable and Accrued Liabilities Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Summary of Carrying Value of IPR&D, Net of Impairment Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Total finance lease liabilities Finance Lease, Liability Property and equipment Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Operating lease right-of-use assets Deferred Tax Liabilities Operating lease right-of-use assets Deferred tax liabilities, operating lease right-of-use assets . Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Liability related to employee severance termination benefits and other contract liabilities Restructuring Reserve Software implementation costs Software and Software Development Costs [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Investments Investment [Text Block] Schedule of Other Nonoperating Income Schedule of Other Nonoperating Income (Expense) [Table Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Tax credit carryforward, amount not subject to expiration Tax Credit Carryforward, Not Subject To Expiration Tax Credit Carryforward, Not Subject To Expiration Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Depreciation of property and equipment (note 7) Depreciation expense Depreciation Issuance of common shares on exercise of stock options (note 10e) (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net deferred tax assets Deferred Tax Assets, Net Issuance of common shares upon vesting of restricted stock units ("RSUs") (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Discount rate Operating Lease, Weighted Average Discount Rate, Percent Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Tax Year 2034 Tax Year Two Thousand Thirty Four [Member] Tax Year Two Thousand Thirty Four [Member] Issuance of common stock upon exercise of pre-funded warrants (note 10c) Issuance of common shares upon exercise of pre-funded warrants Stock Issued During Period, Value, Conversion of Convertible Securities Additional paid-in capital Additional Paid in Capital, Common Stock Exchangeable shares outstanding (in shares) Temporary Equity, Shares Outstanding Clinical Trial Expense Accruals Clinical Trial Expense Accruals [Policy Text Block] Clinical Trial Expense Accruals. Upfront Fee Upfront Fee [Member] Upfront Fee Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Collaborative agreement expansion fee Collaborative Agreement Expansion Fee Collaborative agreement expansion fee. Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Document Information [Line Items] Document Information [Line Items] Temporary Equity [Line Items] Temporary Equity [Line Items] Tax Period [Domain] Tax Period [Domain] Acquired In-Process Research and Development (IPR&D) and Definite-lived Intangible Assets Acquired In Process Research And Development And Definite Lived Intangible Assets [Policy Text Block] Acquired In Process Research And Development And Definite Lived Intangible Assets. Equity Component [Domain] Equity Component [Domain] Canada Emergency Wage Subsidy Canada Emergency Wage Subsidy [Member] Canada Emergency Wage Subsidy Scenario [Axis] Scenario [Axis] Assets measured at fair value Assets, Fair Value Disclosure Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Restructuring Plan [Axis] Restructuring Plan [Axis] Other Expense (Income) Other Operating Income (Expense) [Member] Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Change during the period Indefinite-Lived Intangible Assets, Period Increase (Decrease) Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Supplemental disclosure of non-cash investing and finance items: Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Maximum number of common shares reserved for issuance increase in percentage Maximum Number Of Common Shares Reserved For Issuance Increase In Percentage Maximum number of common shares reserved for issuance increase in percentage. Derivative liability, classified stock options and ESPP Derivative Liability, Classified Stock Options and ESPP Derivative Liability, Classified Stock Options and ESPP Statement of Cash Flows [Abstract] Royalty payments on future global net sales Percentage of Royalty Rate Payments Percentage of royalty rate payments. Entity Address, State or Province Entity Address, State or Province Tax Year 2031 Tax Year Two Thousand Thirty One [Member] Tax Year Two Thousand Thirty One [Member] Platform Technology Transfer and License Agreement Platform Technology Transfer and License Agreement [Member] Platform technology transfer and license agreement. ZW25 Agreement ZW25 Agreement [Member] ZW25 Agreement. Employee Stock Employee Stock [Member] Weighted-average contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share issued price per share (in dollars per share) Shares Issued, Price Per Share Option Exercise Fee Option Exercise Fee [Member] Option Exercise Fee [Member] Award Type [Axis] Award Type [Axis] Award Type [Axis] Maximum exercise fees and milestone payments Collaborative Arrangement, Maximum Exercise Fees and Milestone Payments Collaborative Arrangement, Maximum Exercise Fees and Milestone Payments Celgene Celgene [Member] Celgene. Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Weighted-average common stock outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Net cash provided by / (used in) operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liability (note 15) Current portion Operating Lease, Liability, Current Class of warrant or right, pre-funded (in shares) Class of Warrant or Right, Pre-Funded Pre funded warrants issued in lieu of common shares to underwriters. Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Amounts paid or transferred to payables Contingent Consideration Liability Fair Value Disclosure, Transfers Contingent Consideration Liability Fair Value Disclosure, Transfers Items not involving cash: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Options forfeited and cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares All Currencies [Domain] All Currencies [Domain] Royalty agreement term Royalty Agreement Term Royalty agreement term. Tax Year 2030 Tax Year Two Thousand Thirty [Member] Tax Year Two Thousand Thirty [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of operating programs Number Of Operating Programs Number Of Operating Programs Document Annual Report Document Annual Report Non-capital losses carried forward Deferred Tax Assets Non-Capital Loss Carry Forwards Deferred Tax Assets Non-Capital Loss Carry Forwards Legal Entity [Axis] Legal Entity [Axis] Adjustments to prior year Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Total liabilities Liabilities Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Geographical [Axis] Geographical [Axis] Project Two Project Two [Member] Project Two [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Warrants exercised during period (in shares) Warrants Exercised During Period Warrants Exercised During Period Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Shares issuable upon exercise of stock options (in shares) Common Stock Shares Issuable Upon Exercise Of Stock Option Common stock shares issuable upon exercise of stock option. Off Setting Reversal Off Setting Reversal [Member] Off Setting Reversal Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs (note 10a and 10c) Stock Issued During Period, Value, New Issues Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Revenue Recognized from Strategic Partnerships Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Tax Year 2029 Tax Year Two Thousand Twenty Nine [Member] Tax Year Two Thousand Twenty Nine [Member] Second Therapeutic Second Therapeutic [Member] Second Therapeutic [Member] Portion of fee received Option Fee, Portion Of Fee Received Option Fee, Portion Of Fee Received Components of Property and Equipment Property, Plant and Equipment [Table Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Licensing and technology transfer fee Licensing And Technology Transfer Fee [Member] Licensing And Technology Transfer Fee Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Schedule of Estimated Useful Lives Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block] Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]. Weighted- Average Exercise Price ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Table] Property and equipment useful lives Property, Plant and Equipment, Useful Life Assets Assets, Fair Value Disclosure [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of agreements Number Of Agreements Number Of Agreements Segments [Axis] Segments [Axis] Outstanding, at beginning of period (in dollars per shares) Outstanding, at end of period (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Warrants issued price per pre funded warrant (in dollars per share) Warrants Issued Price Per Pre Funded Warrant Warrants issued price per pre funded warrant. Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred income tax (expense) recovery Deferred Income Tax Expense (Benefit) Total shares authorized (in shares) All Classes Of Stock, Shares Authorized All Classes Of Stock, Shares Authorized Options granted under original plan exercisable period Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Exchange of shares per the Redomiciliation (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Technology Access Fee Technology Service [Member] Financial Instruments Financial Instruments Disclosure [Text Block] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Document Period End Date Document Period End Date Net monetary assets Net Monetary Assets Denominated In Foreign Currency Net Monetary Assets Denominated In Foreign Currency Research Milestone Research Milestone [Member] Research Milestone [Member] Accrued refundable investment tax credits Accrued Investment Tax Credit Accrued investment tax credit. Total assets Assets Net income (loss) per common share (note 4): Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Goods and services tax payable Sales and Excise Tax Payable, Current Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Contract Termination Contract Termination [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Long-term investments (note 5) Long-term investments Long-Term Investments Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] No Trading Symbol Flag No Trading Symbol Flag Government Grants and Credits [Abstract] Government Grants and Credits [Abstract] Employee compensation and vacation accruals Employee-related Liabilities, Current Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Segments [Domain] Segments [Domain] Share issuance costs in equity Income Tax Reconciliation Nondeductible Expense Share Issuance Costs In Equity Income tax reconciliation nondeductible expense share issuance costs in equity. Net Income (Loss) per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Revenue, remaining performance obligation, variable consideration option exercise fees and clinical development and regulatory approval milestone payments amount Revenue, Remaining Performance Obligation, Variable Consideration Option Exercise Fees And Milestone Payments Amount Revenue, Remaining Performance Obligation, Variable Consideration, Option Exercise Fees And Milestone Payments Amount Finance lease liabilities Long-term portion included in other long-term liabilities Finance Lease, Liability, Noncurrent Schedule of Estimated Fair Value of Stock Options Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] 1 to 2 years Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Schedule of Income Tax Expense (Recovery) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Exchangeable stock, shares issued (in shares) Exchangeable Shares, Issued Exchangeable Shares, Issued Iconic Iconic Therapeutics Inc Iconic Therapeutics Inc [Member] Award Type [Domain] Award Type [Domain] Award Type [Domain] Leases Leases Disclosure [Text Block] Leases Disclosure [Text Block] Nonvested award, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Income taxes payable Increase (Decrease) in Income Taxes Restructuring Plan [Domain] Restructuring Plan [Domain] Bispecific Therapeutic Bispecific Therapeutic [Member] Bispecific Therapeutic [Member] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Expected income tax rate Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent Deferred financing fees Payments Of Deferred Financing Fees The amount of costs incurred as part of equity financing transactions that have been paid. CEWS and CERS subsidies Grant CEWS and Rent Subsidy [Member] Grant CEWS and Rent Subsidy Accumulated Impairment Indefinite-lived Intangible Assets Accumulated Impairment [Roll Forward] Indefinite-lived Intangible Assets Accumulated Impairment Entity Registrant Name Entity Registrant Name Issuance of common shares and pre-funded warrants in connection with public offering, net of offering costs (notes 10a and 10d) (in shares) Number of common shares issued (in shares) Stock Issued During Period, Shares, New Issues First Phase 2 Trial First Phase 2 Trial [Member] First Phase 2 Trial Number of common shares issued (in shares) Redomicile Transaction, Number Of Shares Issued Redomicile Transaction, Number Of Shares Issued Contingent consideration Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Total Research and development collaborations Government Grants And Credits government grants and credits Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration Changes In Fair Value Of Contingent Consideration [Table Text Block] Changes In Fair Value Of Contingent Consideration [Table Text Block] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Operating expenses: Operating Expenses [Abstract] Issuance of common stock upon vesting of restricted stock units ("RSUs") (note 10e) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Net operating loss carry forwards Deferred Tax Assets, Operating Loss Carryforwards Asset Class [Domain] Asset Class [Domain] Fair value adjustments upon reclassification of stock options to liabilities Adjustments to Additional Paid in Capital, Fair Value Adjustment, Reclassification of Stock Options to Liabilities Adjustments to Additional Paid in Capital, Fair Value Adjustment, Reclassification of Stock Options to Liabilities Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company General and administrative expenses General and Administrative Expense (Income) General and Administrative Expense (Income) Royalty Royalty [Member] Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Tax Year 2036 Tax Year Two Thousand Thirty Six [Member] Tax Year Two Thousand Thirty Six [Member] Tax Year 2038 Tax Year Two Thousand Thirty Eight [Member] Tax Year Two Thousand Thirty Eight [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Auditor Name Auditor Name Non-capital losses Operating Loss Carryforwards Trading Symbol Trading Symbol Entity File Number Entity File Number First Phase 3 Trial First Phase 3 Trial [Member] First Phase 3 Trial Intangible Assets Intangible Assets Disclosure [Text Block] Stock options Deferred Tax Assets Stock Options Deferred Tax Assets Stock Options Trade payables Accounts Payable, Trade, Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Acquired Indefinite-lived Intangible Assets [Line Items] Acquired Indefinite-Lived Intangible Assets [Line Items] Deferred revenue (note 12) Contract with Customer, Liability, Noncurrent Research and development Research and development expenses Research and Development Expense Increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Federal Tax Incentive Federal Tax Incentive [Member] federal tax incentive [Member] Audit Information [Abstract] Audit Information Research tax credits Research Tax Credit Carryforward [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Vested and settled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Research licenses Research Licenses [Member] Research Licenses Changes due to SR&ED and research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Shares of common stock issuable upon vesting (in shares) Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Atreca Atreca [Member] Atreca Component of Government Grants and Credits Disclosure Of Components Liability In Respect Of Government Grants [Table Text Block] Disclosure Of Components Liability In Respect Of Government Grants Table [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Taxes Income Tax Disclosure [Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Amortization of intangible assets (note 8) Amortization expense on intangible assets Amortization of Intangible Assets Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Collaborative arrangement, number of products Collaborative Arrangement, Number Of Products Collaborative Arrangement, Number Of Products Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures Basic (in dollars per share) Net income (loss) per common share – basic (in dollars per share) Earnings Per Share, Basic Option fee, one time fee Option Fee, One Time Fee Received Option Fee, One Time Fee Received Counterparty Name [Domain] Counterparty Name [Domain] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Tax credit carryforward, amount subject to expiration Investment tax credits Tax Credit Carryforward, Amount Liability Classified Stock Options Liability Classified Stock Options [Member] Liability classified stock options. Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Investments Investments [Member] Fixed lease payment Fixed Lease Payment Fixed lease payment. Other Deferred Tax Assets, Other Schedule of Expiry Details of Investment Tax Credits, Non-Capital Losses and Net Operating Losses for Income Tax Purposes Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block] Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Less accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Long-term prepaid assets Prepaid Expense, Noncurrent Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] LEO Pharma Leo Pharma [Member] Leo Pharma. Changes in non-cash operating working capital: Increase (Decrease) in Operating Capital [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Merck Sharp and Dohme Research Ltd. Merck Sharp and Dohme Research Ltd. [Member] Merck sharp and dohme research ltd. Proceeds from collaboration agreement Payment Received On Collaboration Agreement Payment Received On Collaboration Agreement Accumulated deficit Retained Earnings [Member] Acquired IPR&D, beginning balance Acquired IPR&D, ending balance Acquired In Process Research And Development Acquired in Process Research and Development. Eligible to Receive Scenario, Plan [Member] Schedule Of Accounting Policies [Table] Schedule Of Accounting Policies [Table] Schedule of accounting policies. Exchangeable shares, shares outstanding (in shares) Exchangeable Shares, Outstanding Exchangeable Shares, Outstanding Common stock Common Stock [Member] Maximum eligible employees contribution under ESPP Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Schedule of Stock-based Compensation Expense for Equity Classified Instruments Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Project [Domain] Project [Domain] Contingent liability Business Combination, Contingent Consideration, Liability Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Class of Stock [Axis] Class of Stock [Axis] Income Taxes Income Tax, Policy [Policy Text Block] Liability for Contingent Consideration Liability for Contingent Consideration [Member] Liability for contingent consideration. Statement [Table] Statement [Table] Vested and settled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Renewal term Lessee, Operating Lease, Renewal Term Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Long-term portion of operating lease liability (note 15) Long-term portion Operating Lease, Liability, Noncurrent Accounts Receivable and Expected Credit Losses Accounts Receivable And Expected Credit Losses [Policy Text Block] Accounts Receivable And Expected Credit Losses Statistical Measurement [Axis] Statistical Measurement [Axis] Acquired in-process research and development (note 6) Beginning balance Ending balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Development Milestone Development Milestone [Member] Development milestone. Segment Information Segment Reporting, Policy [Policy Text Block] BeiGene Bei Gene Bei Gene [Member] Bei Gene [Member] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Interest income Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus First Therapeutic First Therapeutic [Member] First Therapeutic [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Intangible assets, net Finite-Lived Intangible Asset, Expected Amortization Finite-Lived Intangible Asset, Expected Amortization Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Preferred Stock Purchase Rights Preferred Stock Purchase Rights [Member] Preferred Stock Purchase Rights Statement [Line Items] Statement [Line Items] Finance lease payments Finance Lease, Principal Payments Research and development deductions and credits Deferred Tax Assets, in Process Research and Development Collaborative arrangement, maximum regulatory milestone payments Collaborative Arrangement, Maximum Regulatory Milestone Payments Collaborative Arrangement, Maximum Regulatory Milestone Payments 2 to 3 years Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three Other income, net (note 13) Total other income, net Nonoperating Income (Expense) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Canada, Dollars Canada, Dollars Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items] SR&ED credits, net SR&ED Credits [Member] SR&ED Credits Computer hardware Computer Hardware [Member] Computer Hardware [Member] Change in fair value of contingent consideration liability (note 17) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Current income tax expense Current Income Tax Expense (Benefit) Operating lease right-of-use assets (note 15) Operating Lease, Right-of-Use Asset Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Auditor Firm ID Auditor Firm ID Contract assets and liabilities Contract Assets And Contract Liabilities [Policy Text Block] Contract assets and contract liabilities. Research, Development, Commercial License Option Milestone Research And Development Regulatory And Sales Related Milestone [Member] Research and development regulatory and sales related milestone. Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] ZW25 and ZW49 Agreements Zw 25 And Zw 49 [Member] Zw 25 and Zw 49 [Member] Operating lease expense Operating Lease, Expense Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number License and Milestone Payments License and Milestone Payments [Member] License and milestone payments [member] Net Indefinite-Lived Intangible Assets [Roll Forward] Summary of Stock Options Granted Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income (loss) from operations Operating Income (Loss) Initial adoption of new accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Employees Stock Purchase Plan Employees Stock Purchase Plan [Member] Employees Stock Purchase Plan [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Document Information [Table] Document Information [Table] Tax Year 2037 Tax Year Two Thousand Thirty Seven [Member] Tax Year Two Thousand Thirty Seven [Member] Common shares, outstanding (in shares) Common Stock, Shares, Outstanding Goodwill (note 6) Goodwill Maximum milestone payments and tiered royalties Collaborative Arrangement, Maximum Milestone Payments and Tiered Royalties Collaborative Arrangement, Maximum Milestone Payments and Tiered Royalties Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Government Grants and Credits Government Grants And Tax Credits [Policy Text Block] Government grants and tax credits. Acquired IPR&D, Change during the period Indefinite-Lived Intangible Assets Acquired Difference between domestic and foreign tax rate Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Outside basis difference in foreign subsidiary Deferred Tax Liabilities, Outside Basis Difference Deferred Tax Liabilities, Outside Basis Difference Royalty percentage earned from sales of product Royalty Percentage Earned From Product Sales Royalty percentage earned from product sales. Investments [Line Items] Investments [Line Items] Investments. IPR&D and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Income tax recovery (expense), net (note 14) Income tax (expense) recovery Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Less: valuation allowance Deferred Tax Assets, Valuation Allowance Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Deferred tax liability (note 14)  Deferred tax liabilities Deferred Income Tax Liabilities, Net Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Additional paid-in capital Additional Paid-in Capital [Member] Impairment of Long-Lived Assets Impairment Of Long Lived Assets [Policy Text Block] Impairment Of Long Lived Assets Policy Text Block. Document Fiscal Period Focus Document Fiscal Period Focus Investment tax credits Investment Tax Credit Carryforward [Member] Option exercised intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Kairos Acquisition Kairos Acquisition [Member] Kairos Acquisition Maximum number of common shares reserved for issuance (in shares) Maximum Number Of Common Shares Reserved For Issuance Maximum number of common shares reserved for issuance under new plan. Acquired IPR&D Indefinite-lived Intangible Assets Acquired [Roll Forward] Indefinite-lived Intangible Assets Acquired Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Option fee, total Option Fee, Total Option Fee, Total Fair value of liability-classified stock options Derivative Liability, Subject to Master Netting Arrangement, before Offset Expected average life of options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Issuance of common stock through employee stock purchase plan (note 10f) Proceeds from Issuance of Shares Under Employee Share Purchase Plan Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, employee share purchase plan. ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Partner Revenue Partner Revenue [Member] Partner Revenue License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement Beginning balance Ending balance Indefinite Lived Intangible Assets Impairment Indefinite Lived Intangible Assets Impairment Accounts payable and accrued liabilities (note 9) Total Accounts Payable and Accrued Liabilities, Current Milestone Payment Milestone Payment [Member] Milestone payment [member] Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2022 (no par value, unlimited shares at December 31, 2021; 63,059,501 and 46,633,935 shares issued and outstanding at December 31, 2022 and 2021, respectively (note 10b). Common Stock, Value, Issued Schedule Of Accounting Policies [Line Items] Schedule Of Accounting Policies [Line Items] Schedule of accounting policies. Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Preferred stock Preferred Stock [Member] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Cross License Agreement Cross License Agreement [Member] Cross license agreement. Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total other income, net Other Operating Income (Expense), Net Collaborative arrangement, royalty percentage Collaborative Arrangement, Royalty Percentage Collaborative Arrangement, Royalty Percentage Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Increase  (decrease) in fair value of liability for contingent consideration Contingent Consideration Fair Value Adjustments Contingent consideration fair value adjustments. Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents The Restructuring The Restructuring [Member] The Restructuring Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Proceeds from stock options exercised Proceeds from Stock Options Exercised Basic Net Income (Loss) Available to Common Stockholders, Basic Common shares, issued (in shares) Common Stock, Shares, Issued Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Remaining unamortized compensation expense, weighted-average period Weighted-average contractual term, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue (note 12) Contract with Customer, Liability, Current Cash Equivalents Cash Equivalents [Member] Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Foreign exchange gain Foreign Currency Transaction Gain (Loss), before Tax License Agreement License Agreement Terms [Member] Income Statement Location [Domain] Income Statement Location [Domain] Current portion included in other current liabilities Finance Lease, Liability, Current Facility Closing Facility Closing [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Tax Year 2035 Tax Year Two Thousand Thirty Five [Member] Tax Year Two Thousand Thirty Five [Member] Amendment Flag Amendment Flag Definite-lived intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Net cash (used in) / provided by investing activities Net Cash Provided by (Used in) Investing Activities Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Investment Type [Axis] Investment Type [Axis] Investments Investment, Policy [Policy Text Block] Issuance of common stock through employee stock purchase plan (note 10f) Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Tax Year 2033 Tax Year Two Thousand Thirty Three [Member] Tax Year Two Thousand Thirty Three [Member] Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Issuance of common stock on exercise of stock options (note 10e) Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Commercial and Development Milestones Commercial and Development Milestones [Member] Commercial and Development Milestones [Member] Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Weighted- Average Contractual Term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable outstanding stock options (in shares) Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number British Columbia BRITISH COLUMBIA Deferred tax assets liabilities before valuation allowance Deferred Tax Assets Liabilities Before Valuation Allowance Deferred tax assets (liabilities) before valuation allowance. Milestone Performance Milestone [Member] Performance Milestone [Member] Janssen Janssen Biotech, Inc. Janssen [Member] Janssen [Member] Percentage of discounted purchase price of average market price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Employee Severance Employee Severance [Member] Impairment loss Operating Lease, Impairment Loss Operating lease, term of contract Lessee, Operating Lease, Term of Contract Project [Axis] Project [Axis] Issuance of common shares through employee share purchase plan (note 10f) (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Thereafter Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five Counterparty Name [Axis] Counterparty Name [Axis] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Number of liability classified stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Licensing fee Licensing Fee [Member] Licensing Fee Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net (note 7) Property and equipment, net Property, Plant and Equipment, Net Operating lease payments Operating Lease, Payments Currency [Axis] Currency [Axis] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Office equipment Office Equipment [Member] Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Other Income, net Other Income and Other Expense Disclosure [Text Block] Operating lease liabilities Increase Decrease in Operating Lease Liabilities Increase decrease in operating lease liabilities. Government Grants And Credits [Line Items] Government Grants And Credits [Line Items] Government Grants And Credits Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Issuance of common stock on exercise of stock options (note 10e) Stock Issued During Period, Value, Stock Options Exercised Other Other Nonoperating Income (Expense) Liability for contingent consideration (note 17) Business Combination, Contingent Consideration, Liability, Noncurrent Restructuring Restructuring and Related Activities Disclosure [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Income tax payable (note 14) Accrued Income Taxes, Current Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Grant Grant [Member] Milestone payment Milestone Payment Milestone Payment Commercial Sales Milestones Commercial Sales Milestones [Member] Commercial Sales Milestones [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred financing fees Deferred Financing Fee Deferred financing fee. Total current assets Assets, Current Within 1 year Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Entity Small Business Entity Small Business Other Commitments [Table] Other Commitments [Table] Number of reporting units Number of Reporting Units Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Amortization and impairment of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Revenue: Revenues [Abstract] Intangible assets, net (note 8) Intangible assets, net Finite-Lived Intangible Assets, Net BMS BMS [Member] BMS Canada Emergency Rent Subsidy Canada Emergency Rent Subsidy [Member] Canada Emergency Rent Subsidy Adjustment for dilutive effect of liability classified stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements, Liability Classified Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements, Liability Classified Tax Year 2032 Tax Year Two Thousand Thirty Two [Member] Tax Year Two Thousand Thirty Two [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Software Computer software Computer Software, Intangible Asset [Member] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Stock-based compensation for equity classified instruments Allocated Share Based Compensation Expense Income Allocated share based compensation expense (income). Glaxo Smith Kline Intellectual Property Development Ltd Glaxo SmithKline Intellectual Property Development Ltd [Member] Glaxo smith kline intellectual property development. 3 to 4 years Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four Aggregate intrinsic value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Warrants exercised (in shares) Warrants Exercised In Period Warrants Exercised In Period Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Other Long-term Liabilities Other Noncurrent Liabilities [Table Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable The Redomicile Transactions (note 1, note 10b) (in shares) Stock Issued During Period, Shares, Exchange Of Shares Per The Redomiciliation Stock Issued During Period, Shares, Exchange Of Shares Per The Redomiciliation Title of 12(b) Security Title of 12(b) Security Variable lease payment Variable Lease, Payment Accrued legal and professional fees Accrued Legal And Professional Fees, Current Accrued legal and professional fees, current. Laboratory equipment Laboratory Equipment [Member] PropertyPlantAndEquipmentByTypeAxis=zyme Short-term investments (note 5) Short-Term Investments Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Total operating expenses Costs and Expenses Total Liabilities, Other than Long-Term Debt, Noncurrent Payables and Accruals [Abstract] Payables and Accruals [Abstract] Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Liability at the beginning of the period Liability at end of the period Contingent Consideration Liability Fair Value Disclosure Contingent Consideration Liability Fair Value Disclosure Revenue, remaining performance obligation, variable consideration commercial milestone payments amount Revenue, Remaining Performance Obligation, Variable Consideration Commercial Milestone Payments Amount Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestone Payments, Amount Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Schedule of Balance Sheet Classification of Lease Liabilities Schedule of Lease Liabilities Classification [Table Text Block] Schedule of lease liabilities classification. Business Combination and Goodwill Business Combinations And Goodwill [Policy Text Block] Business Combinations And Goodwill. Exchangeable shares Exchangeable Shares [Member] Exchangeable Shares Collaborative arrangement, maximum commercial milestone payments Collaborative Arrangement, Maximum Commercial Milestone Payments Collaborative Arrangement, Maximum Commercial Milestone Payments Research Development and Commercial Milestones Research Development and Commercial Milestones [Member] Research, development and commercial milestones member Commercial Milestones Commercial Milestones [Member] Commercial milestones. 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Net deferred tax liabilities Deferred Tax Liabilities, Net Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Acquisition of intangible assets Payments to Acquire Intangible Assets Weighted-average common stock outstanding (note 4): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Net proceeds from issuance Sale of Stock, Consideration Received on Transaction Restructuring charges Restructuring Charges Total lease liabilities Lease Liability Lease Liability Other Other Accrued Liabilities, Noncurrent Aggregate intrinsic vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant [Member] Inducement Plan Inducement Plan [Member] Inducement Plan Auditor Location Auditor Location Nature of Operations Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Jazz Jazz [Member] Jazz Proceeds from public offerings, net of issuance costs (note 10a) Proceeds from Issuance of Common Stock Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Individual penalty, threshold percentage Share-Based Payment Arrangement, Individual Penalty, Threshold Percentage Share-Based Payment Arrangement, Individual Penalty, Threshold Percentage Number of potential products to developed and commercialized Number of potential products developed and commercialized Number of potential products developed and commercialized. Liabilities Liabilities, Fair Value Disclosure [Abstract] Compensation charge Compensation recovery Share-Based Payment Arrangement, Expense Commitments and contingencies (note 17) Commitments and Contingencies Adjustment for change in fair value of liability classified stock options Fair Value, Option, Adjustment For Change In Fair Value Of Liability Classified Stock Options Fair Value, Option, Adjustment For Change In Fair Value Of Liability Classified Stock Options Security Exchange Name Security Exchange Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price License Option License [Member] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Offering Offering [Member] Offering. Operating lease liability Deferred Tax Assets Operating Lease Liability Deferred tax assets, operating lease liability. Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2022 (December 31, 2021: nil) (note 10b). Preferred Stock, Value, Issued Tax Year 2040 Tax Year 2040 [Member] Tax Year 2040 Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and Administrative Expenses General and Administrative Expense [Member] Research and development collaborations (note 12) Research and development collaborations Revenue from Contract with Customer, Excluding Assessed Tax Issuance of common shares upon exercise of pre-funded warrants (note 10) (in shares) Issuance of common shares upon exercise of pre-funded warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer GICs Guaranteed Investment Contract [Member] Common stock, capital shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Cover [Abstract] Leases Lessee, Leases [Policy Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Entity Voluntary Filers Entity Voluntary Filers Accrued research and development expenses Accrued Research Expenses Current Accrued research expenses, current. Goodwill, impairment loss Goodwill, Impairment Loss Purchases of long-term investments Payments to Acquire Long-Term Investments Shares granted with respect to maximum fixed amount equal, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Stock-Based Compensation Stock Based Compensation [Policy Text Block] Stock Based Compensation. Restructuring and Related Activities [Abstract] Research and Development Milestone Research and Development Milestone [Member] Research and development Milestone member Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Canadian Dollar Under the New Option Stock Plan CAD Dollars Under The New Stock Option Plan [Member] CAD dollars under the new stock option plan. Deferred income tax expense (recovery) Increase (Decrease) in Deferred Income Taxes Deferred revenue Deferred Tax Assets, Deferred Income Non-vested, beginning balance (in dollars per share) Non-vested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Investments [Domain] Investments [Domain] Forecast Forecast [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Payment for royalty Proceeds From Royalties Buy Out in Future Period Cash receivable from royalties buy out during future periods. Total liabilities and stockholders’ equity Liabilities and Equity Schedule of Significant Components of the Deferred Income Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Unrealized foreign exchange gain Foreign Currency Transaction Gain (Loss), Unrealized Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Adjustment for dilutive effect of equity classified stock options and RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Total amount contributed by ESPP participants Contributions To Employee Share Purchase Plan contributions to employee share purchase plan. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gross deferred tax assets Deferred Tax Assets, Gross Level 2 Fair Value, Inputs, Level 2 [Member] Research support payments and other service Research Support Payments And Other Service [Member] Research support payments and other [member] Unamortized compensation expense related to unvested options Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense Share based compensation by share based payment award unamortized compensation expense. Change in fair value of liability classified instruments Increase (decrease) in fair value of liability classified equity instruments Increase (decrease) in fair value of liability classified equity instruments. 4 to 5 years Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five Tax Year 2039 Tax Year 2039 [Member] Tax Year 2039. No Trading Symbol - PSPR Current Fiscal Year End Date Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted Net Income (Loss) Available to Common Stockholders, Diluted Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in dollars per share) Net income (loss) per common share – diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Research Support Payments License and Service [Member] Shares available for issuance, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payments of stock issuance costs Payments of Stock Issuance Costs Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Options vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Delivery of Licenses, Initial Technology Transfer and BTC Data Transfer Delivery Of Licenses, Initial Technology Transfer And BTC Data Transfer [Member] Delivery Of Licenses, Initial Technology Transfer And BTC Data Transfer Balance, beginning of year Balance, end of year Unrecognized Tax Benefits Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance IPR&D Deferred Tax Liabilities, Intangible Assets Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Share issue costs Deferred Tax Assets Share Issue Costs Deferred tax assets share issue costs. Share-based Payment Arrangement, Restricted Stock Unit, Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Original Stock Option Plan Original Stock Option Plan [Member] Original stock option plan [member] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Number of shares issued to underwriters Stock Issued During Period, Shares, Issued for Services Share-based compensation arrangement by share-based payment award, expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Research and License Agreement Research and License Agreement [Member] Research and license agreement. Other income (expense): Nonoperating Income (Expense) [Abstract] Tax Year 2041 Tax Year 2041 [Member] Tax Year 2041 Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Net redemptions (purchases) of short-term investments Payments for (Proceeds from) Short-Term Investments Exchangeable shares, no par value, 1,424,533 issued and outstanding shares at December 31, 2022 (December 31, 2021: nil) (note 10b). Exchangeable Shares, Value, Issued Exchangeable Shares, Value, Issued Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Contract liabilities Contract with Customer, Liability Change in fair value of investments in equity instruments Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] U.S Dollar Under the New Option Stock Plan U S dollars under the New Stock Option Plan [Member] Us dollars under the new stock option plan. Over-Allotment Option Over-Allotment Option [Member] Change during the period Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Table] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards Table [Table] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Table] Arrangement Other than Collaborative Arrangement Other than Collaborative [Member] Class of Stock [Domain] Class of Stock [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Non-cash consideration from licensing agreement Licensing Agreement, Noncash Consideration Licensing Agreement, Noncash Consideration United States of America, Dollars United States of America, Dollars Institutional investors penalty, threshold percentage Share-Based Payment Arrangement, Institutional Investors Penalty, Threshold Percentage Share-Based Payment Arrangement, Institutional Investors Penalty, Threshold Percentage Building Building [Member] Entity Tax Identification Number Entity Tax Identification Number Short Term Investments [Table] Schedule of Investments [Table] Maximum exposure to credit risk for accounts receivable Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure Schedule of Non-Vested Stock Option Activity Schedule of Nonvested Share Activity [Table Text Block] Eli Lilly and Company Eli Lilly And Company [Member] Eli lilly and company. Outstanding at beginning of period (in shares) Outstanding, at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Gross deferred tax liabilities Deferred Tax Liabilities, Gross Zymeworks BC Inc Zymeworks BC Inc [Member] Zymeworks BC Inc Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table] Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Common stock issued upon exercise of warrants (in shares) Common Stock Issued Upon Exercise Of Warrants, Shares Common Stock Issued Upon Exercise Of Warrants, Shares Aggregate intrinsic value ($) Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Commercial paper Commercial Paper [Member] Property and equipment Deferred Tax Assets, Property, Plant and Equipment 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Weighted- average grant date fair value ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Daiichi Sankyo, Co., Ltd Daiichi Sankyo, Co., Ltd [Member] Daiichi sankyo, co., ltd. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Research, Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Tax Period [Axis] Tax Period [Axis] Entity [Domain] Entity [Domain] The Redomicile Transactions (note 1, note 10b) Stock Issued During Period, Value, Exchange Of Shares Per The Redomiciliation Stock Issued During Period, Value, Exchange Of Shares Per The Redomiciliation Patents and Intellectual Property Costs Patents And Intellectual Property Costs [Policy Text Block] Patents and intellectual property costs policy. City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Impairment of Intangible Assets (Excluding Goodwill) Impairment of Intangible Assets (Excluding Goodwill) Other Commitments [Line Items] Other Commitments [Line Items] Non-vested, beginning balance (in shares) Non-vested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair value of consideration allocated to a group of contracts that were considered as a single contract Fair Value Of Consideration Allocated, Group Of Contracts Fair value of consideration allocated to a group of contracts that were considered as a single contract. Sale of Stock [Axis] Sale of Stock [Axis] Computed taxes at United States statutory income tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Purchase of shares under ESPP, maximum limit for each employee Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Financial liabilities measured at fair value Financial Liabilities Fair Value Disclosure Asset Class [Axis] Asset Class [Axis] Net income (loss) per share Earnings Per Share, Policy [Policy Text Block] Stock-based compensation (note 10e) Share-Based Payment Arrangement, Noncash Expense Finance expenses Finance Expense Income Finance expense (income). Derivative Liability Roll Forward [Roll Forward] Derivative Liability Roll Forward [Roll Forward] Derivative Liability Roll Forward Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Disclosure [Table] Options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Tax Year 2042 Tax Year 2042 [Member] Tax Year 2042 Other long-term liabilities (note 9) Other Liabilities, Noncurrent Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Research and Development Expense Research and Development Expense [Member] Recovery of Cost of Development Work Recovery Of Cost Of Development Work [Member] Recovery Of Cost Of Development Work 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Summary of Calculation of Diluted Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Options forfeited and cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Government Grants and Credits Government Grants And Credits Disclosure [Text Block] Government Grants And Credits Disclosure [Text Block] Reduction in head count percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Customer [Domain] Customer [Domain] Research and Development Expenses Research and Development Expenses [Member] Research and Development Expenses Milestone and Other Payments Milestone and Other Payments [Member] Milestone and other payments [member] Accounts Payable and Accrued Liabilities